Halozyme Therapeutics, Inc. (HALO)
100.67
-1.01
(-0.99%)
USD |
NASDAQ |
Nov 12, 16:00
100.66
-0.01
(-0.01%)
After-Hours: 07:52
Halozyme Therapeutics Net Income (Quarterly) : 247.05M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 247.05M |
| June 30, 2026 | 229.91M |
| March 31, 2026 | 150.05M |
| December 31, 2025 | -141.59M |
| September 30, 2025 | 175.22M |
| June 30, 2025 | 165.16M |
| March 31, 2025 | 118.10M |
| December 31, 2024 | 137.01M |
| September 30, 2024 | 137.01M |
| June 30, 2024 | 93.24M |
| March 31, 2024 | 76.82M |
| December 31, 2023 | 85.39M |
| September 30, 2023 | 81.84M |
| June 30, 2023 | 74.75M |
| March 31, 2023 | 39.62M |
| December 31, 2022 | 57.70M |
| September 30, 2022 | 61.63M |
| June 30, 2022 | 22.68M |
| March 31, 2022 | 60.11M |
| December 31, 2021 | 66.77M |
| September 30, 2021 | 216.59M |
| June 30, 2021 | 91.46M |
| March 31, 2021 | 27.90M |
| December 31, 2020 | 73.16M |
| September 30, 2020 | 36.21M |
| Date | Value |
|---|---|
| June 30, 2020 | 25.82M |
| March 31, 2020 | -6.103M |
| December 31, 2019 | -34.40M |
| September 30, 2019 | -25.02M |
| June 30, 2019 | -14.62M |
| March 31, 2019 | 1.796M |
| December 31, 2018 | -2.126M |
| September 30, 2018 | -27.85M |
| June 30, 2018 | -22.89M |
| March 31, 2018 | -27.46M |
| December 31, 2017 | 123.88M |
| September 30, 2017 | 2.749M |
| June 30, 2017 | -30.76M |
| March 31, 2017 | -32.90M |
| December 31, 2016 | -27.39M |
| September 30, 2016 | -28.95M |
| June 30, 2016 | -26.88M |
| March 31, 2016 | -19.82M |
| December 31, 2015 | 4.318M |
| September 30, 2015 | -24.46M |
| June 30, 2015 | 3.019M |
| March 31, 2015 | -15.11M |
| December 31, 2014 | -5.274M |
| September 30, 2014 | -20.28M |
| June 30, 2014 | -16.27M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AVITA Medical, Inc. | -6.222M |
| Iovance Biotherapeutics, Inc. | -22.27M |
| Merck & Co., Inc. | 5.067B |
| Neurocrine Biosciences, Inc. | 206.50M |
| TG Therapeutics, Inc. | 55.46M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 492.97M |
| Total Expenses (Quarterly) | 245.92M |
| EPS Diluted (Quarterly) | 2.015 |
| Enterprise Value | 13.65B |
| Gross Profit Margin (Quarterly) | 77.28% |
| Profit Margin (Quarterly) | 50.11% |
| Earnings Yield | 3.90% |
| Operating Earnings Yield | 8.38% |
| Normalized Earnings Yield | 5.991 |